These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16810619)

  • 41. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 42. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
    Wong GC; Lee LH
    Am J Hematol; 2006 Aug; 81(8):624-6. PubMed ID: 16823822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
    Kellner A; Dombi P; Illes A; Demeter J; Homor L; Ercsei I; Simon Z; Karadi E; Herczeg J; Gy Korom V; Gasztonyi Z; Szerafin L; Udvardy M; Egyed M
    Eur J Haematol; 2020 Oct; 105(4):408-418. PubMed ID: 32557810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
    Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
    Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
    Hernández-Boluda JC; Pereira A; Cervantes F; Gómez M; Arellano-Rodrigo E; Alvarez-Larrán A; Ferrer-Marín F; Kerguelen A; Márquez JA; Antelo ML; Besses C;
    Ann Hematol; 2013 Jun; 92(6):771-5. PubMed ID: 23354997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of the myeloproliferative disorders : distinguishing data from dogma.
    Green AR; Vassiliou GS; Curtin N; Campbell PJ
    Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
    [No Abstract]   [Full Text] [Related]  

  • 50. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 51. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
    Mazzucconi MG; Baldacci E; Latagliata R; Breccia M; Paoloni F; Di Veroli A; Cedrone M; Anaclerico B; Villivà N; Porrini R; Montefusco E; Andriani A; Montanaro M; Scaramucci L; Spadea A; Rago A; Cimino G; Spirito F; Santoro C
    Eur J Haematol; 2020 Sep; 105(3):335-343. PubMed ID: 32441419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
    Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Ruiz-Reyes G; Chernoff SG
    Mayo Clin Proc; 1998 Nov; 73(11):1125. PubMed ID: 9818051
    [No Abstract]   [Full Text] [Related]  

  • 53. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
    Le Calloch R; Lacut K; Le Gall-Ianotto C; Nowak E; Abiven M; Tempescul A; Dalbies F; Eveillard JR; Ugo V; Giraudier S; Guillerm G; Lippert E; Berthou C; Ianotto JC
    Haematologica; 2018 Apr; 103(4):607-613. PubMed ID: 29246923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
    Adam R; Priglinger M; Harrington T; Gottlieb D; Krause M
    J Stroke Cerebrovasc Dis; 2014; 23(5):e373-4. PubMed ID: 24582788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Other secondary sequelae of treatments for myeloproliferative disorders.
    Gilbert HS
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):22-7. PubMed ID: 12096354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pathogenesis and management of essential thrombocythaemia.
    Green AR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():36-9. PubMed ID: 10907463
    [No Abstract]   [Full Text] [Related]  

  • 58. Essential thrombocythemia in a child: diagnostic and therapeutic dilemma.
    Asghar R; Behzad E; Mohammad GA
    Saudi Med J; 2005 Nov; 26(11):1806-8. PubMed ID: 16311671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
    Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
    Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
    [No Abstract]   [Full Text] [Related]  

  • 60. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.